KR100677837B1 - 약리학적으로 활성이 있는 물질 또는 이와 다른 물질을 2상 방출하기 위한 필름 형태의 약제 - Google Patents
약리학적으로 활성이 있는 물질 또는 이와 다른 물질을 2상 방출하기 위한 필름 형태의 약제 Download PDFInfo
- Publication number
- KR100677837B1 KR100677837B1 KR1020027006105A KR20027006105A KR100677837B1 KR 100677837 B1 KR100677837 B1 KR 100677837B1 KR 1020027006105 A KR1020027006105 A KR 1020027006105A KR 20027006105 A KR20027006105 A KR 20027006105A KR 100677837 B1 KR100677837 B1 KR 100677837B1
- Authority
- KR
- South Korea
- Prior art keywords
- layer
- film
- polymer
- medicament
- release
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 17
- 230000002051 biphasic effect Effects 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims description 5
- 239000003814 drug Substances 0.000 claims abstract description 41
- 229920000642 polymer Polymers 0.000 claims abstract description 32
- 239000011159 matrix material Substances 0.000 claims abstract description 15
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 9
- 238000000576 coating method Methods 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 238000004088 simulation Methods 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 229920003086 cellulose ether Polymers 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 239000002831 pharmacologic agent Substances 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 238000007639 printing Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 4
- 230000003111 delayed effect Effects 0.000 claims 2
- 239000011149 active material Substances 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 235000013599 spices Nutrition 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 abstract description 2
- 239000000470 constituent Substances 0.000 description 9
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 239000008199 coating composition Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 229920002959 polymer blend Polymers 0.000 description 5
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001477 hydrophilic polymer Polymers 0.000 description 4
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- RCQXSQPPHJPGOF-UHFFFAOYSA-N caffeine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C RCQXSQPPHJPGOF-UHFFFAOYSA-N 0.000 description 3
- 229960002031 caffeine citrate Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000004408 titanium dioxide Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920005601 base polymer Polymers 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Laminated Bodies (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (19)
- 약리학적으로 활성이 있는 물질, 방향제(odorizer), 향신료(flavoring), 감미료 및 청량 효과(refreshing effect)를 갖는 물질로 이루어진 군에서 선택된 하나 이상의 물질을 함유하고, 상기 물질은, 상기 약제가 인간이나 동물의 생리액, 또는 상기 생리액의 인공 시뮬레이션(artificial simulation)을 포함하는 액체 환경(liquid surrounding)에 놓이면 2상(biphasic) 방식으로 상기 약제로부터 방출되는, 필름 형태의 중합체를 기재로 한 약제에 있어서,- 상기 약제는, 상기 하나 이상의 물질을 함유하는 두 개의 중합체 매트릭스 층이 적층체(laminate)를 형성하도록 결합되어 이루어지고,- 상기 매트릭스 층은 그 중합체 조성이 다르고 상기 물질의 방출 속도가 다르며, 느리게 방출하는 층으로 불리는 적어도 하나의 층은, 급속히 방출하는 층으로 불리는 다른 하나의 층보다 느린 속도로 상기 활성 물질을 방출하는 지연된 방출 속도를 가지며,- 상기 급속히 방출하는 층의 매트릭스는 폴리비닐 알코올로 이루어지고,- 상기 느리게 방출하는 층의 매트릭스는 셀룰로오스 에테르로 이루어지는것을 특징으로 하는, 필름 형태의 중합체를 기재로 한 약제.
- 삭제
- 삭제
- 삭제
- 삭제
- 제 1항에 있어서,상기 급속히 방출하는 층의 용해 속도는, 15분 이내에 상기 층의 10cm2 면적이 생리액 또는 그 인공 시뮬레이션에서 용해되도록 조절된 것을 특징으로 하는, 필름 형태의 중합체를 기재로 한 약제.
- 제 1항에 있어서,상기 느리게 방출하는 층의 용해 속도는, 생리액 또는 그 인공 시뮬레이션에서 상기 층의 10cm2 이하의 면적을 용해시키는데 적어도 15분이 필요하도록 조절된 것을 특징으로 하는, 필름 형태의 중합체를 기재로 한 약제.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제 1항에 있어서,상기 약제는, 5 내지 500㎛ 범위의 두께를 갖는 것을 특징으로 하는, 필름 형태의 중합체를 기재로 한 약제.
- 제 1항에 기재된 필름 형태의 약제를 제조하는 방법에 있어서,a) 방출될 물질이 첨가된, 급속히 방출하는 층에 적합한 중합체 용액을 제조하는 단계와,b) 상기 용액을 나이프 또는 롤러 도포 또는 분무 공정에 의해 불활성 기판 위에 코팅한 후, 건조하여 상기 급속히 방출하는 필름 층을 형성하는 단계와,c) 방출될 물질이 첨가된, 느리게 방출하는 층에 적합한 중합체 용액을 제조하는 단계와,d) 상기 급속히 방출하는 필름 층 위에 상기 용액을 나이프 또는 롤러 도포 또는 분무 공정 또는 프린팅에 의해 코팅한 후, 건조하여 상기 느리게 방출하는 필름 층을 형성하는 단계로이루어진, 필름 형태의 약제 제조 방법.
- 제 14항에 있어서,a) 및 b) 단계에서, 처음에는 상기 느리게 방출하는 필름 층을 제조하고, 그 후 상기 층이 c) 및 d) 단계처럼 상기 급속히 방출하는 필름 층으로 코팅되는 것을 특징으로 하는, 필름 형태의 약제 제조 방법.
- 제 14항 또는 제 15항에 있어서,제 1 필름 층의 제조는 나이프 또는 롤러 도포, 분무 또는 분출 공정에 의해 불활성 기판에 도포된 중합체 용융물(polymer melt)로부터 시작된 후, 건조 또는 냉각하고, 중합체 용액으로부터 추가 층이 코팅되는 것을 특징으로 하는, 필름 형태의 약제 제조 방법.
- 제 14항 또는 제 15항에 있어서,상기 느리게 방출하는 층으로부터 상기 물질의 방출은, 상기 물질 입자의 크기를 증가시키거나, 상기 물질 또는 상기 활성 성분을 코팅 또는 마이크로캡슐화하거나, 유사한 효과를 갖는 약리학적 기술 수단에 의해 지연되는 것을 특징으로 하는, 필름 형태의 약제 제조 방법.
- 제 1항, 제 6항, 제 7항 또는 제 13항 중 어느 한 항에 기재된 필름 형태의 약제를 포함하는, 약리학적으로 활성이 있는 성분을 인체 또는 동물의 체액이나 상기 체액의 인공 시뮬레이션 안에 방출하기 위한, 약제.
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19954421.2 | 1999-11-12 | ||
DE19954421A DE19954421A1 (de) | 1999-11-12 | 1999-11-12 | Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020058008A KR20020058008A (ko) | 2002-07-12 |
KR100677837B1 true KR100677837B1 (ko) | 2007-02-05 |
Family
ID=7928785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020027006105A KR100677837B1 (ko) | 1999-11-12 | 2000-11-03 | 약리학적으로 활성이 있는 물질 또는 이와 다른 물질을 2상 방출하기 위한 필름 형태의 약제 |
Country Status (15)
Country | Link |
---|---|
US (3) | US7037526B1 (ko) |
EP (2) | EP1227802B1 (ko) |
JP (2) | JP4825385B2 (ko) |
KR (1) | KR100677837B1 (ko) |
CN (1) | CN100531724C (ko) |
AT (2) | ATE320245T1 (ko) |
AU (1) | AU777870B2 (ko) |
CA (1) | CA2391393C (ko) |
CY (1) | CY1105051T1 (ko) |
DE (3) | DE19954421A1 (ko) |
DK (1) | DK1227802T3 (ko) |
ES (2) | ES2344954T3 (ko) |
IL (2) | IL149572A0 (ko) |
PT (1) | PT1227802E (ko) |
WO (1) | WO2001035934A1 (ko) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19954421A1 (de) | 1999-11-12 | 2001-05-31 | Lohmann Therapie Syst Lts | Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen |
AU2003235294B2 (en) * | 2002-05-16 | 2008-04-17 | Kyukyu Pharmaceutical Co., Ltd. | Quickly soluble film preparations |
US20040131662A1 (en) | 2003-11-12 | 2004-07-08 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US8999372B2 (en) | 2002-11-14 | 2015-04-07 | Cure Pharmaceutical Corporation | Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use |
US20040191302A1 (en) | 2003-03-28 | 2004-09-30 | Davidson Robert S. | Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films |
US9561182B2 (en) | 2003-08-22 | 2017-02-07 | Cure Pharmaceutical Corporation | Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals |
DE20307771U1 (de) * | 2003-05-19 | 2004-09-23 | Cofresco Frischhalteprodukte Gmbh & Co. Kg | Beschichtung und Beutel |
US20050186257A1 (en) * | 2004-02-20 | 2005-08-25 | Todd Manegold | Dissolvable film and method of manufacture |
KR20080081088A (ko) | 2005-12-29 | 2008-09-05 | 안트로제네시스 코포레이션 | 태반 줄기세포와 제2 세포원으로부터 얻은 줄기세포의 공동배양 |
CN103060263B (zh) | 2005-12-29 | 2016-03-16 | 人类起源公司 | 胎盘干细胞群 |
US20070175484A1 (en) * | 2006-01-30 | 2007-08-02 | Staab Robert J | Condoms for beneficial agents delivery |
US7993918B2 (en) | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
KR20210127819A (ko) | 2007-09-28 | 2021-10-22 | 안트로제네시스 코포레이션 | 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법 |
CN105766891A (zh) | 2008-08-20 | 2016-07-20 | 人类起源公司 | 改进的细胞组合物及制备所述组合物的方法 |
MX2011001991A (es) | 2008-08-20 | 2011-03-29 | Anthrogenesis Corp | Tratamiento de la apoplejia utilizando celulas placentarias aisladas. |
JP5869342B2 (ja) | 2008-11-19 | 2016-02-24 | アンスロジェネシス コーポレーション | 羊膜由来接着細胞 |
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
KR102017009B1 (ko) | 2009-06-12 | 2019-09-02 | 선오비온 파마슈티컬스 인코포레이티드 | 설하 아포모르핀 |
WO2011094181A1 (en) | 2010-01-26 | 2011-08-04 | Anthrogenesis Corporation | Treatment of bone-related cancers using placental stem cells |
WO2012009422A1 (en) | 2010-07-13 | 2012-01-19 | Anthrogenesis Corporation | Methods of generating natural killer cells |
CN103298459A (zh) * | 2010-09-23 | 2013-09-11 | 莫诺索尔克斯有限公司 | 用于直接在包装表面上形成药用产品的方法和系统 |
EA031156B1 (ru) | 2010-12-16 | 2018-11-30 | Суновион Фармасьютикалз Инк. | Сублингвальные пленки |
JP5831239B2 (ja) | 2012-01-16 | 2015-12-09 | Tdk株式会社 | バスバー及び電子機器 |
US9822257B2 (en) | 2012-07-23 | 2017-11-21 | Crayola Llc | Dissolvable films and methods of using the same |
EP3622960A1 (en) | 2013-02-05 | 2020-03-18 | Celularity, Inc. | Natural killer cells from placenta |
ES2962827T3 (es) | 2015-02-05 | 2024-03-21 | Ath Australia Ltd | Formulaciones que comprenden reactivos que contienen mercurio para detectar una enfermedad |
WO2016172095A1 (en) | 2015-04-21 | 2016-10-27 | Cynapsus Therapeutics, Inc. | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
CN105997958B (zh) * | 2016-07-12 | 2019-03-26 | 中国人民解放军白求恩医务士官学校 | 一种口腔外用制剂及其制备方法 |
WO2020077081A1 (en) * | 2018-10-11 | 2020-04-16 | Vitiprints, LLC | Dissolvable composition having indicia |
US20200281889A1 (en) * | 2019-03-07 | 2020-09-10 | Terpene Therapeutics Inc. | Edible Film Comprising Adjacent Conjoined Strips |
EP4076417A4 (en) * | 2019-12-20 | 2024-02-21 | Oye Therapeutics Inc | CAFFEINE CITRATE FORMULATIONS |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61280423A (ja) * | 1985-06-05 | 1986-12-11 | Kiyuukiyuu Yakuhin Kogyo Kk | 口腔内粘膜貼付剤 |
US4713243A (en) * | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
JPH01279838A (ja) * | 1988-04-30 | 1989-11-10 | Kiyuukiyuu Yakuhin Kogyo Kk | 塩化リゾチーム含有歯肉炎・歯槽膿漏用貼付剤 |
US5085865A (en) * | 1989-04-12 | 1992-02-04 | Warner-Lambert Company | Sustained release pharmaceutical preparations containing an analgesic and a decongestant |
US4985467A (en) * | 1989-04-12 | 1991-01-15 | Scotfoam Corporation | Highly absorbent polyurethane foam |
ATE195075T1 (de) * | 1991-11-22 | 2000-08-15 | Procter & Gamble Pharma | Risedronat enthaltende arzneimittel mit verzögerter wirkstoffabgabe |
US5393528A (en) * | 1992-05-07 | 1995-02-28 | Staab; Robert J. | Dissolvable device for contraception or delivery of medication |
IT1264696B1 (it) * | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
AU7568394A (en) * | 1993-08-19 | 1995-03-14 | Cygnus Therapeutic Systems | Water-soluble pressure-sensitive mucoadhesive and devices provided therewith for emplacement in a mucosa-lined body cavity |
JP3496727B2 (ja) * | 1993-12-27 | 2004-02-16 | 救急薬品工業株式会社 | 製剤用基剤 |
JP3629283B2 (ja) * | 1994-02-15 | 2005-03-16 | ポーラ化成工業株式会社 | 皮膚外用剤 |
DE19503336C2 (de) * | 1995-02-02 | 1998-07-30 | Lohmann Therapie Syst Lts | Arzneiform zur Abgabe von Wirkstoffen an Wunden, Verfahren zu ihrer Herstellung und ihre Verwendung |
IT1276689B1 (it) | 1995-06-09 | 1997-11-03 | Applied Pharma Res | Forma farmaceutica solida ad uso orale |
IT1282576B1 (it) * | 1996-02-06 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili |
SE9603667D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
EP1079813B1 (en) * | 1998-04-29 | 2005-02-09 | Virotex Corporation | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
US6277401B1 (en) * | 1999-05-07 | 2001-08-21 | U.S. Dermatologics, Inc. | Drug delivery device |
DE19954421A1 (de) * | 1999-11-12 | 2001-05-31 | Lohmann Therapie Syst Lts | Filmförmige Zubereitung zur biphasigen Freisetzung pharmakologisch wirksamer oder anderer Substanzen |
-
1999
- 1999-11-12 DE DE19954421A patent/DE19954421A1/de not_active Withdrawn
-
2000
- 2000-11-03 IL IL14957200A patent/IL149572A0/xx active IP Right Grant
- 2000-11-03 CA CA002391393A patent/CA2391393C/en not_active Expired - Lifetime
- 2000-11-03 DE DE50015917T patent/DE50015917D1/de not_active Expired - Lifetime
- 2000-11-03 WO PCT/EP2000/010861 patent/WO2001035934A1/de active IP Right Grant
- 2000-11-03 EP EP00975993A patent/EP1227802B1/de not_active Expired - Lifetime
- 2000-11-03 DK DK00975993T patent/DK1227802T3/da active
- 2000-11-03 JP JP2001537927A patent/JP4825385B2/ja not_active Expired - Fee Related
- 2000-11-03 AT AT00975993T patent/ATE320245T1/de active
- 2000-11-03 AT AT05026782T patent/ATE465722T1/de active
- 2000-11-03 KR KR1020027006105A patent/KR100677837B1/ko active IP Right Grant
- 2000-11-03 AU AU13916/01A patent/AU777870B2/en not_active Expired
- 2000-11-03 ES ES05026782T patent/ES2344954T3/es not_active Expired - Lifetime
- 2000-11-03 US US10/129,837 patent/US7037526B1/en not_active Expired - Lifetime
- 2000-11-03 CN CNB008167354A patent/CN100531724C/zh not_active Expired - Lifetime
- 2000-11-03 ES ES00975993T patent/ES2260068T3/es not_active Expired - Lifetime
- 2000-11-03 EP EP05026782A patent/EP1634587B1/de not_active Expired - Lifetime
- 2000-11-03 DE DE50012412T patent/DE50012412D1/de not_active Expired - Lifetime
- 2000-11-03 PT PT00975993T patent/PT1227802E/pt unknown
-
2002
- 2002-05-09 IL IL149572A patent/IL149572A/en unknown
-
2006
- 2006-04-24 US US11/408,958 patent/US9084731B2/en not_active Expired - Fee Related
- 2006-06-14 CY CY20061100798T patent/CY1105051T1/el unknown
-
2011
- 2011-03-09 JP JP2011051364A patent/JP2011144193A/ja active Pending
-
2015
- 2015-06-17 US US14/742,171 patent/US9211267B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2344954T3 (es) | 2010-09-10 |
EP1227802B1 (de) | 2006-03-15 |
CN1407888A (zh) | 2003-04-02 |
ATE320245T1 (de) | 2006-04-15 |
IL149572A0 (en) | 2002-11-10 |
JP4825385B2 (ja) | 2011-11-30 |
WO2001035934A1 (de) | 2001-05-25 |
AU1391601A (en) | 2001-05-30 |
JP2011144193A (ja) | 2011-07-28 |
IL149572A (en) | 2007-08-19 |
CN100531724C (zh) | 2009-08-26 |
CY1105051T1 (el) | 2009-11-04 |
EP1634587B1 (de) | 2010-04-28 |
DE50015917D1 (de) | 2010-06-10 |
DE50012412D1 (de) | 2006-05-11 |
AU777870B2 (en) | 2004-11-04 |
EP1634587A2 (de) | 2006-03-15 |
DK1227802T3 (da) | 2006-07-24 |
JP2003514009A (ja) | 2003-04-15 |
ES2260068T3 (es) | 2006-11-01 |
DE19954421A1 (de) | 2001-05-31 |
KR20020058008A (ko) | 2002-07-12 |
US20150272904A1 (en) | 2015-10-01 |
US20060198878A1 (en) | 2006-09-07 |
US9084731B2 (en) | 2015-07-21 |
CA2391393A1 (en) | 2001-05-25 |
PT1227802E (pt) | 2006-08-31 |
CA2391393C (en) | 2008-07-15 |
ATE465722T1 (de) | 2010-05-15 |
EP1634587A3 (de) | 2008-09-17 |
US7037526B1 (en) | 2006-05-02 |
US9211267B2 (en) | 2015-12-15 |
EP1227802A1 (de) | 2002-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100677837B1 (ko) | 약리학적으로 활성이 있는 물질 또는 이와 다른 물질을 2상 방출하기 위한 필름 형태의 약제 | |
US7332230B1 (en) | Multilayer preparation in film form, consisting of hydrophilic polymers, for the rapid release of active ingredients | |
JP3157190B2 (ja) | 薬剤のための味マスキング及び持効性皮膜 | |
JP2003513906A5 (ko) | ||
CZ148396A3 (en) | Preparation intended for controllable release of active compounds and the use thereof | |
UA79578C2 (en) | Controlled release composition containing galantamine, process for the preparation thereof, dosage form and packaging | |
US20120100278A1 (en) | Films for use as dosage forms | |
JP2005507856A (ja) | 薬学的に活性な薬剤の浸透送達のためのシステム | |
KR19980063026A (ko) | 에멀젼 방법에 의한 다공성 매트릭스형 서방성 제제의 제조방법 | |
RU2411035C2 (ru) | Лекарственная форма с модифицированным высвобождением 6-метил-2-этил-3-гидроксипиридина сукцината | |
JP2541835B2 (ja) | 持続放出型薬理組成物の製法およびこれにより得られる組成物 | |
Dave et al. | A review on promising novel drug delivery system-bioadhesive drug delivery system | |
JPH06128147A (ja) | 水難溶性薬品の溶解性改善方法およびそれにより得られた薬品組成物 | |
JP2024522779A (ja) | マクロライドの非ナノ粒子適用形態 | |
SI9200070A (sl) | Retardni pripravek za urapidil |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130125 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140117 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150116 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160119 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170113 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180119 Year of fee payment: 12 |